PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Borsa Italiana 04:04:59 2024-05-17 pm EDT | ||
| 1.056 EUR | +13.18% |
|
| Current month | +1.29% | ||
| 1 month | -26.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1.097 | +17.58% |
| 24-05-16 | 0.933 | +10.28% |
| 24-05-15 | 0.846 | -7.94% |
| 24-05-14 | 0.919 | -2.03% |
| 24-05-13 | 0.938 | -31.03% |
Real-time Borsa Italiana
Last update May 17, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| F43955 | |
| ISIN | DE000VM8AEA3 |
| Date issued | 2024-02-06 |
| Strike | 976.1 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.77 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.54 € |
|---|---|
| Lowest since issue | 0.563 € |
| Spread | 0.509 € |
| Spread % | 38.77% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- F43955 Certificat
